Rodrigo Pirmez
Research Subjects
Rodrigo Pirmez has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Bruna Duque-Estrada
Department of Dermatology, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil
6 shared publications- Antonella Tosti
University of Miami Miller School of Medicine
4 shared publications C.T. Sodré
Department of Dermatology, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil
4 shared publicationsTullia Cuzzi
Department of Dermatology, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil
4 shared publicationsDanielle C. Quintella
Department of Dermatology, Pathology Consultant, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil
3 shared publications- Leonardo Spagnol Abraham
Department of Dermatology, Hospital Universitario de Brasilia, Brasilia, Brasil
3 shared publications
Latest Publications
- Open Access
- 30 November 2023
- Published by Principles and Practice of Clinical Research in Principles and Practice of Clinical Research Journal
- Vol. 9 (3)
When Authorship Becomes a Burden: Learning About Authorship Issues in Scientific Articles
- 30 November 2023
- Published by Principles and Practice of Clinical Research in Principles and Practice of Clinical Research Journal
- Vol. 9 (3)
Open AccessWhen Authorship Becomes a Burden: Learning About Authorship Issues in Scientific Articles
- 15 August 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , S9-S15
The dermatoscope in the hair clinic: Trichoscopy of scarring and nonscarring alopecia
- 15 August 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , S9-S15
The dermatoscope in the hair clinic: Trichoscopy of scarring and nonscarring alopecia
- 2 December 2020
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 7 (2) , 112-114
Eyebrow Regrowth in Patients with Frontal Fibrosing Alopecia Treated with Low-Dose Oral Minoxidil
Introduction: The eyebrows are an important facial feature that shape one’s physical appearance and play a role in non-verbal communication. Partial or complete eyebrow loss is seen in most patients with frontal fibrosing alopecia (FFA). Despite the scarring nature of FFA, eyebrow hair regrowth has been previously reported. Nevertheless, treatment options and supporting evidence remain scarce. Case Presentation: We report eyebrow regrowth in 7 patients with FFA treated with low-dose oral minoxidil (OM). Conclusion: Low-dose OM could be a promising adjunctive therapy for treatment of the eyebrows in patients with FFA, particularly in early disease.
- 2 December 2020
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 7 (2) , 112-114
Eyebrow Regrowth in Patients with Frontal Fibrosing Alopecia Treated with Low-Dose Oral Minoxidil
Introduction: The eyebrows are an important facial feature that shape one’s physical appearance and play a role in non-verbal communication. Partial or complete eyebrow loss is seen in most patients with frontal fibrosing alopecia (FFA). Despite the scarring nature of FFA, eyebrow hair regrowth has been previously reported. Nevertheless, treatment options and supporting evidence remain scarce. Case Presentation: We report eyebrow regrowth in 7 patients with FFA treated with low-dose oral minoxidil (OM). Conclusion: Low-dose OM could be a promising adjunctive therapy for treatment of the eyebrows in patients with FFA, particularly in early disease.
- 1 January 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (1) , e21-e22
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation
- 1 January 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (1) , e21-e22
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation
- 1 February 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (2) , e45-E45
Histopathology of facial papules in frontal fibrosing alopecia and therapeutic response to oral isotretinoin
- 1 February 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (2) , e45-E45
Histopathology of facial papules in frontal fibrosing alopecia and therapeutic response to oral isotretinoin
- 1 January 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (1) , e19-E19
Acknowledging the pseudo “fringe sign” in frontal fibrosing alopecia has diagnostic and prognostic implications
- 1 January 2018
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (1) , e19-E19
Acknowledging the pseudo “fringe sign” in frontal fibrosing alopecia has diagnostic and prognostic implications
- Open Access
- 23 November 2017
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 4 (3) , 174-176
Ingrown Hairs: A Recurrent Trichoscopic Feature in Scarring Alopecias
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- 23 November 2017
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 4 (3) , 174-176
Open AccessIngrown Hairs: A Recurrent Trichoscopic Feature in Scarring Alopecias
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Open Access
- 4 November 2017
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 4 (3) , 145-149
Facial Papules in Frontal Fibrosing Alopecia: Beyond Vellus Hair Follicle Involvement
Background: Frontal fibrosing alopecia (FFA) is considered a variant of lichen planopilaris affecting mainly the frontotemporal hairline. Since the first report in 1994, several other clinical features have been associated with the disease, such as facial papules (FP). Even though FP have been linked to facial vellus hair follicle involvement, how this finding alone could lead to the formation of clinically evident FP in FFA patients had not yet been addressed. Objective: To describe histopathological findings of FP in the context of FFA and to highlight features that may be linked to their clinical formation. Methods: Cutaneous FP biopsies of FFA patients performed between January 2016 and May 2017 were retrieved from our pathology database and reexamined by 2 pathologists. Results: Histological sections of thirteen 3.0-mm punch biopsy specimens (2 horizontally and 11 vertically oriented) were collected from 7 patients. Eleven specimens demonstrated prominent sebaceous glands and 10 dilated sebaceous ducts. Pinkus acid orcein staining revealed reduction and fragmentation of the elastic fibers in 12 samples and, in 7 of these, this finding was observed in both the papillary and reticular dermis, particularly around sebaceous lobules. Vellus hair follicle involvement was only seen in 2 samples. Conclusions: Prominent sebaceous lobules with dilated ducts associated with an abnormal elastic framework seem to be the main explanation for the formation of FP in the context of FFA.
- 4 November 2017
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 4 (3) , 145-149
Open AccessFacial Papules in Frontal Fibrosing Alopecia: Beyond Vellus Hair Follicle Involvement
Background: Frontal fibrosing alopecia (FFA) is considered a variant of lichen planopilaris affecting mainly the frontotemporal hairline. Since the first report in 1994, several other clinical features have been associated with the disease, such as facial papules (FP). Even though FP have been linked to facial vellus hair follicle involvement, how this finding alone could lead to the formation of clinically evident FP in FFA patients had not yet been addressed. Objective: To describe histopathological findings of FP in the context of FFA and to highlight features that may be linked to their clinical formation. Methods: Cutaneous FP biopsies of FFA patients performed between January 2016 and May 2017 were retrieved from our pathology database and reexamined by 2 pathologists. Results: Histological sections of thirteen 3.0-mm punch biopsy specimens (2 horizontally and 11 vertically oriented) were collected from 7 patients. Eleven specimens demonstrated prominent sebaceous glands and 10 dilated sebaceous ducts. Pinkus acid orcein staining revealed reduction and fragmentation of the elastic fibers in 12 samples and, in 7 of these, this finding was observed in both the papillary and reticular dermis, particularly around sebaceous lobules. Vellus hair follicle involvement was only seen in 2 samples. Conclusions: Prominent sebaceous lobules with dilated ducts associated with an abnormal elastic framework seem to be the main explanation for the formation of FP in the context of FFA.
- Open Access
- 28 April 2017
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 3 (4) , 171-174
Trichoscopy of Steroid-Induced Atrophy
Intralesional corticosteroid (IL-CS) injections have been used to treat a variety of dermatological and nondermatological diseases. Although an important therapeutic tool in dermatology, a number of local side effects, including skin atrophy, have been reported following IL-CS injections. We recently noticed that a subset of patients with steroid-induced atrophy presented with ivory-colored areas under trichoscopy. We performed a retrospective analysis of trichoscopic images and medical records from patients presenting ivory-colored areas associated with atrophic scalp lesions. In this paper, we associate this feature with the presence of steroid deposits in the dermis and report additional trichoscopic features of steroid-induced atrophy on the scalp, such as prominent blood vessels and visualization of hair bulbs.
- 28 April 2017
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 3 (4) , 171-174
Open AccessTrichoscopy of Steroid-Induced Atrophy
Intralesional corticosteroid (IL-CS) injections have been used to treat a variety of dermatological and nondermatological diseases. Although an important therapeutic tool in dermatology, a number of local side effects, including skin atrophy, have been reported following IL-CS injections. We recently noticed that a subset of patients with steroid-induced atrophy presented with ivory-colored areas under trichoscopy. We performed a retrospective analysis of trichoscopic images and medical records from patients presenting ivory-colored areas associated with atrophic scalp lesions. In this paper, we associate this feature with the presence of steroid deposits in the dermis and report additional trichoscopic features of steroid-induced atrophy on the scalp, such as prominent blood vessels and visualization of hair bulbs.